Dianthus Therapeutics Inc
DNTH21.550USD
+0.960+4.66%
交易中 （美東）報價延遲15分鐘
692.31M總市值
虧損本益比TTM
關於 Dianthus Therapeutics Inc 公司
Dianthus Therapeutics, Inc. 是一家臨牀階段的生物技術公司，致力於推進抗體補體療法，以治療嚴重的自身免疫性疾病。該公司致力於設計和提供具有更高選擇性和效力的單克隆抗體。該公司已啓動 DNTH103（一種潛在的活性 C1s 抑制劑）在全身性重症肌無力中的 2 期試驗，並計劃啓動其他神經肌肉適應症的 2 期試驗，包括多竈性運動神經病和慢性炎症性脫髓鞘性多發性神經病。其候選產品 DNTH103 是一種臨牀階段的高效、高選擇性和完全人源化的單克隆免疫球蛋白 G4，具有皮摩爾結合親和力，旨在選擇性地僅與 C1s 補體蛋白的活性形式結合。DNTH103 採用 YTE 半衰期延長技術設計，Fc 結構域中有特定的三個氨基酸變化，並具有藥代動力學 (PK) 特徵。
公司簡介
公司代碼DNTH
公司名稱Dianthus Therapeutics Inc
上市日期Jun 21, 2018
CEOMr. Marino Garcia
員工數量78
證券類型Ordinary Share
年結日Jun 21
公司地址7 Times Square
城市NEW YORK
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編10036
電話19299994055
網址https://dianthustx.com/
公司代碼DNTH
上市日期Jun 21, 2018
CEOMr. Marino Garcia
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
--
--
Mr. John C. King
Mr. John C. King
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Ryan Savitz
Mr. Ryan Savitz
Chief Financial Officer, Chief Business Officer Treasurer
Chief Financial Officer, Chief Business Officer Treasurer
--
--
Mr. Adam M. Veness, Esq., J.D.
Mr. Adam M. Veness, Esq., J.D.
Senior Vice President, General Counsel, Company Secretary
Senior Vice President, General Counsel, Company Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Simrat Randhawa, M.D.
Dr. Simrat Randhawa, M.D.
Chief Medical Officer
Chief Medical Officer
4.00K
--
Dr. Simon Read, Ph.D.
Dr. Simon Read, Ph.D.
Independent Director
Independent Director
--
--
Ms. Anne McGeorge
Ms. Anne McGeorge
Independent Director
Independent Director
--
--
Mr. Sujay Kango
Mr. Sujay Kango
Independent Director
Independent Director
--
--
Mr. Marino Garcia
Mr. Marino Garcia
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.60%
RA Capital Management, LP
8.91%
Fairmount Funds Management LLC
8.40%
Bain Capital Life Sciences Investors, LLC
8.36%
Deep Track Capital LP
7.33%
Other
53.39%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.60%
RA Capital Management, LP
8.91%
Fairmount Funds Management LLC
8.40%
Bain Capital Life Sciences Investors, LLC
8.36%
Deep Track Capital LP
7.33%
Other
53.39%
股東類型
持股股東
佔比
Hedge Fund
42.38%
Investment Advisor
38.35%
Venture Capital
20.56%
Investment Advisor/Hedge Fund
17.48%
Corporation
7.86%
Research Firm
0.87%
Pension Fund
0.11%
Bank and Trust
0.09%
Family Office
0.05%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
225
41.08M
127.75%
+683.80K
2025Q1
235
40.76M
126.74%
+1.19M
2024Q4
225
37.90M
128.07%
+500.72K
2024Q3
228
34.16M
116.90%
-861.66K
2024Q2
212
32.37M
110.91%
+1.86M
2024Q1
216
28.72M
99.95%
+5.46M
2023Q4
215
12.76M
88.36%
-987.59K
2023Q3
226
11.26M
78.30%
+6.74M
2023Q2
233
1.90M
50.21%
-2.51M
2023Q1
239
1.94M
51.29%
-1.60M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
4.37M
13.6%
+43.33K
+1.00%
Mar 31, 2025
RA Capital Management, LP
2.87M
8.91%
+1.00M
+53.60%
Mar 31, 2025
Fairmount Funds Management LLC
2.70M
8.4%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
2.69M
8.36%
--
--
Mar 31, 2025
Deep Track Capital LP
2.36M
7.33%
+2.36M
--
Mar 31, 2025
Octagon Capital Advisors LP
2.34M
7.28%
+231.50K
+10.97%
Mar 31, 2025
Point72 Asset Management, L.P.
1.89M
5.89%
+407.36K
+27.40%
Apr 16, 2025
VR Adviser, LLC
1.74M
5.42%
--
--
Mar 31, 2025
Avidity Partners Management LP
1.72M
5.35%
-1.15M
-40.10%
Mar 31, 2025
Vestal Point Capital, LP
1.70M
5.29%
+625.07K
+58.15%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
ALPS Medical Breakthroughs ETF
0.41%
SPDR S&P Biotech ETF
0.13%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
iShares Micro-Cap ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
iShares Russell 2000 Value ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
iShares Neuroscience and Healthcare ETF
佔比1.02%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.87%
ALPS Medical Breakthroughs ETF
佔比0.41%
SPDR S&P Biotech ETF
佔比0.13%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.08%
iShares Micro-Cap ETF
佔比0.08%
Avantis US Small Cap Equity ETF
佔比0.06%
iShares Russell 2000 Value ETF
佔比0.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Sep 11, 2023
Merger
16<1
Sep 11, 2023
Merger
16<1
Sep 11, 2023
Merger
16<1
Sep 11, 2023
Merger
16<1
公告日期
類型
比率
Sep 11, 2023
Merger
16<1
Sep 11, 2023
Merger
16<1
Sep 11, 2023
Merger
16<1
Sep 11, 2023
Merger
16<1
